Stoke Therapeutics Inc at Bank of America Global Healthcare Conference Transcript
(audio in progress) of the Bank of America 2023 healthcare conference. I'm Greg Harrison, one of the biotech analysts here at B of A. And this morning, we have Stoke Therapeutics with us represented by Barry Ticho, Chief Medical Officer. Barry, if you'd like to make some opening remarks, that would be great, and then we can jump into Q&A.
Thanks, Greg. Well, it's pleasure to be here. We appreciate the invitation. And it's a pleasure for me to be here speaking on behalf of Stoke Therapeutics. It's very exciting time for us right now. We have upcoming a readout from our STK-001 Phase 1/2a studies in patients with Dravet syndrome. This is potentially the first new medicine that's treating the underlying cause of Dravet syndrome.
And we have a readout coming out in the middle of this year that will help us understand more about the potential for the medicine. And then, we're planning for starting Phase 3 to test STK-001 in patients with Dravet
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
